Previous 10 | Next 10 |
HANOVER, MD, May 18, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”) today announces it has received guidance from the U.S. Food and Drug Administration (“FDA”) regarding the Company’s next tri...
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, will be presenting at the annual Digestive Disease Week (“DDW...
PCS12852 Shown to be Safe and Efficacious in Phase 2 Proof-of-Concept Trial in Gastroparesis Patients PCS12852 Improved Both Gastroparesis Symptom Scores and Gastric Emptying Rate HANOVER, MD, April 28, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. ...
2023-03-31 16:14:06 ET Processa Pharmaceuticals, Inc. (PCSA) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Jim Stanker - CFO David Young - President & CEO Conference Call Participants Naz Rahman - Maxim Group Pr...
Processa Pharmaceuticals (NASDAQ: PCSA) , a developer of next-generation chemotherapy drugs that provide a better safety-efficacy profile than widely used FDA-approved counterparts, is reporting on its full-year 2022 financial results and has also noted key accomplishments for the year. According...
Company focused on the development of Next Generation Chemotherapy drugs in 2023 and out-licensing/business development efforts for non-oncology assets. Dose escalations continue for Next Generation Capecitabine with no observed adverse events associated with the catabolites of capecitabi...
Processa Pharmaceuticals (NASDAQ: PCSA) , a developer of next-generation chemotherapy drugs that provide a better safety-efficacy profile than widely used FDA-approved counterparts, is hosting a conference call to discuss 2022 year-end results and company updates. The call, which will also be ava...
HANOVER, MD, March 23, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a developer of Next Generation Chemotherapy drugs that provide a better safety-efficacy profile than their widely used FDA-approved counterpar...
Processa Pharmaceuticals (NASDAQ: PCSA) , a developer of next-generation chemotherapies (“NGCs”), has dosed the first patient in its NGC-Capecitabine (combination of PCS6422 and capecitabine) 300 mg dose group. This group is designed to obtain critical information on the drug exposu...
The 300 mg dose group will provide more information on the drug exposure vs adverse event relationship which is critical to FDA approval given the FDA’s Project Optimus Oncology initiative. P atients treated with Next Generation Chemotherapy-Capecitabine have NO...
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals Inc. Website:
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, has named a new chief financial officer. According to the announcement, Russell L. Skibsted has accepted the new...
HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the appointment of Ru...
Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial. The...